Heartflow (NASDAQ:HTFL) CEO Sells $657,005.44 in Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $29.12, for a total value of $657,005.44. Following the sale, the chief executive officer directly owned 519,397 shares in the company, valued at $15,124,840.64. This represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Friday, April 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $26.72, for a total value of $602,856.64.
• On Wednesday, March 18th, John C.M. Farquhar sold 9,725 shares of Heartflow stock. The stock was sold at an average price of $25.00, for a total value of $243,125.00.
• On Tuesday, March 10th, John C.M. Farquhar sold 12,837 shares of Heartflow stock. The stock was sold at an average price of $22.66, for a total value of $290,886.42.

Heartflow Stock Performance

Shares of HTFL opened at $28.32 on Friday. The business’s 50-day moving average is $27.28 and its two-hundred day moving average is $28.87. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $41.22. The company has a market capitalization of $2.44 billion and a P/E ratio of -9.11.

Heartflow (NASDAQ:HTFL) last posted its earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.08. The firm had revenue of $52.59 million for the quarter. The business’s revenue for the quarter was up 41.3% compared to the same quarter last year. Analysts forecast that Heartflow, Inc. will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Baillie Gifford & Co. purchased a new position in Heartflow in the 3rd quarter worth approximately $101,182,000. TD Asset Management Inc purchased a new position in Heartflow in the 3rd quarter worth approximately $2,692,000. Fred Alger Management LLC purchased a new position in Heartflow in the 3rd quarter worth approximately $9,997,000. New York State Common Retirement Fund purchased a new position in Heartflow in the 3rd quarter worth approximately $4,015,000. Finally, JPMorgan Chase & Co. purchased a new position in Heartflow in the 3rd quarter worth approximately $13,887,000.

Wall Street Analysts Forecast Growth

HTFL has been the topic of several recent analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, March 19th. Wells Fargo & Company increased their target price on shares of Heartflow from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday. Canaccord Genuity Group lowered their target price on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a research note on Friday. Finally, William Blair initiated coverage on shares of Heartflow in a research note on Monday, May 4th. They set an “outperform” rating on the stock. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Heartflow presently has an average rating of “Moderate Buy” and a consensus price target of $37.00.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.